Loading…
Loading…
Diversify Advisory Services LLC lifted its stake in shares of NYLIM Hedge Multi-Strategy Tracker ETF (NYSEARCA:QAI) by 145.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 146,907 shares of the company's stock after purchasing an additional 87,081 shares during
Aspiriant LLC purchased a new position in shares of NYLIM Hedge Multi-Strategy Tracker ETF (NYSEARCA:QAI) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 211,530 shares of the company's stock, valued at approximately $7,624,000. Aspiriant LLC owned 0.76% of
Toronto, Ontario--(Newsfile Corp. - September 21, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen", "QAI" or the "Company"), an innovator in physiological AI screening and developer of an intelligence platform for clinical and occupational health applications, is pleased to announce that it has agreed to settle an aggregate of $681,000 of indebtedness owing to certain directors and officers of the Company (the "Debt Settlement") through the issuance of approximately 9.73 million common shares of the Company (the "Common Shares") at a deemed price of $0.07 per Common Share (the "Settlement Price"). The Settlement Price represents a premium of approximately 180% to the $0.025 closing price of the Common Shares on the CSE on September 18, 2026, and a premium of approximately 40% to the $0.05 price per unit under the Company's non-brokered private placement that closed on September 9, 2026.
Toronto, Ontario--(Newsfile Corp. - September 9, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, is pleased to announce the closing of the final tranche of its previously announced non-brokered private placement. The Company is pleased to announce that it has completed the final tranche of its previously announced non-brokered private placement through the issuance of 6,153,256 units (the "Units") at a price of $0.05 per Unit for gross proceeds of approximately $307,662.80.
Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - QScreen AI Inc. (CSE: QAI) (OTC: PMEDF) (FSE: 3QP) ("QScreen" or the "Company") today announced completion of the tiered screening architecture at the core of its commercialization strategy. The architecture is fully implemented in the Company's browser-based platform and is now being demonstrated to prospective institutional partners through the Company's US channel process, where a first signed evaluation agreement remains the stated near-term milestone.
Toronto, Ontario--(Newsfile Corp. - July 14, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or the "Company") now holds two granted US patents covering its core impairment-detection method, after the United States Patent and Trademark Office granted the Company US Patent No. 12,640,164, "Systems and Methods for Detecting Impairment of an Individual," on May 26, 2026.
Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions in Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933"). Introduced by the Canadian Securities Administrators (CSA), the pilot program under CBO 51-933 allows eligible venture issuers to voluntarily transition from quarterly to semi-annual financial reporting.
Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, is pleased to announce the closing of the first tranche of its previously announced non-brokered private placement. The Company is pleased to announce that it has completed the first tranche of its previously announced non-brokered private placement through the issuance of 4,876,400 units (the "Units") at a price of $0.05 per Unit for gross proceeds of approximately $243,820.